{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:27:14Z","timestamp":1768037234077,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infants with Down syndrome (DS) have an altered immune response. We aimed to characterise the inflammatory response in infants with DS and congenital heart disease (CHD) peri-operatively in comparison to infants with CHD and a normal chromosomal complement, and to healthy infants pre-operatively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Infants with DS\/CHD, infants without DS but with CHD (CHD only) and healthy infants were prospectively recruited and serial serum cytokines evaluated peri-operatively using multiplex ELISA: tumour necrosis factor (TNF)-\u03b1 and TNF-\u03b2; interferon (IFN)-\u03b3, interleukin (IL)-1\u03b1, IL-2, IL-6, IL-8, IL-18, IL-1\u03b2, IL-10, and IL-1ra; vascular endothelial growth factor (VEGF); granulocyte macrophage colony-stimulating factor (GM-CSF); and erythropoietin (EPO).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ninety-four infants were recruited including age-matched controls (<jats:italic>n<\/jats:italic>\u2009=\u200910), DS\/CHD (<jats:italic>n<\/jats:italic>\u2009=\u200955), and CHD only (<jats:italic>n<\/jats:italic>\u2009=\u200929). Children with DS\/CHD had significantly lower concentrations of several cytokines (IL-10, IL-6, IL-8, IL-1\u03b2, VEGF) in the pre- and post-operatively vs CHD only and controls. EPO and GM-CSF were significantly higher in DS\/CHD (<jats:italic>p<\/jats:italic> value &lt;0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Children with DS\/CHD had significantly lower concentrations of several cytokines compared to controls or children with CHD only. EPO and GM-CSF were significantly higher in children with DS\/CHD. The assessment of the immune response may be suitable for the predictable clinical outcomes in these children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Impact<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>This study demonstrated that children with Down syndrome (DS) and congenital heart disease (CHD) have significant alterations in pro-inflammatory and anti-inflammatory immune responses peri-operatively.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>These changes may contribute to adverse clinical outcomes, including sepsis, chylothorax, and autoimmunity. They may impact the pathogenesis and outcome post-operatively and long term in this population.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Children with DS and CHD have significantly lower cytokine concentrations, increased EPO and GM-CSF, and decreased VEGF pre- and post-operatively. Assessing their inflammatory state peri-operatively may facilitate the development of a predictive model that can inform tailored management of these infants using novel therapies including immunomodulation.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41390-022-02000-3","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:04:36Z","timestamp":1648602276000},"page":"1716-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Infants with Down syndrome and congenital heart disease have altered peri-operative immune responses"],"prefix":"10.1038","volume":"92","author":[{"given":"Lyudmyla","family":"Zakharchenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afif","family":"EL-Khuffash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashanti","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Padden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orla","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor J.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"2000_CR1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/bdra.20735","volume":"88","author":"SE Parker","year":"2010","unstructured":"Parker, S. E. et al. Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res. A Clin. Mol. Teratol. 88, 1008\u20131016 (2010).","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"2000_CR2","first-page":"248","volume":"107","author":"R Ni She","year":"2014","unstructured":"Ni She, R. & Filan, P. M. Trisomy 21-incidence and outcomes in the first year, in Ireland today. Ir. Med. J. 107, 248\u2013249 (2014).","journal-title":"Ir. Med. J."},{"key":"2000_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fped.2020.00073","volume":"27","author":"D Huggard","year":"2020","unstructured":"Huggard, D., Doherty, D. G. & Molloy, E. J. Immune dysregulation in children with Down syndrome. Front. Pediatr. 27, 73 (2020).","journal-title":"Front. Pediatr."},{"key":"2000_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apa.15153","volume":"109","author":"N Lagan","year":"2020","unstructured":"Lagan, N. et al. Multiorgan involvement and management in children with Down syndrome. Acta Paediatr. 109, 1096\u20131111 (2020).","journal-title":"Acta Paediatr."},{"key":"2000_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12865-018-0270-z","volume":"19","author":"D Huggard","year":"2018","unstructured":"Huggard, D. et al. Altered endotoxin responsiveness in healthy children with Down syndrome. BMC Immunol. 19, 31 (2018).","journal-title":"BMC Immunol."},{"key":"2000_CR6","doi-asserted-by":"crossref","unstructured":"Huggard, D. et al. Altered Toll-like receptor signalling in children with Down syndrome. Mediators Inflamm. 2019, 4068734 (2019).","DOI":"10.1155\/2019\/4068734"},{"key":"2000_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood-2004-01-0273","volume":"104","author":"BA Hesser","year":"2004","unstructured":"Hesser, B. A. et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 104, 149\u2013158 (2004).","journal-title":"Blood"},{"key":"2000_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jpeds.2009.12.006","volume":"156","author":"BL Bloemers","year":"2010","unstructured":"Bloemers, B. L., Van Bleek, G. M., Kimpen, J. L. & Bont, L. Distinct abnormalities in the innate immune system of children with Down syndrome. J. Pediatr. 156, 804\u2013809 (2010).","journal-title":"J. Pediatr."},{"key":"2000_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jped.2016.04.012","volume":"93","author":"ME Zaki","year":"2017","unstructured":"Zaki, M. E., El-Bassyouni, H. T., Tosson, A. M., Youness, E. & Hussein, J. Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects. J. Pediatr. 93, 100\u2013104 (2017).","journal-title":"J. Pediatr."},{"key":"2000_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","volume":"45","author":"JM Zhang","year":"2007","unstructured":"Zhang, J. M. & An, J. Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 45, 27\u201337 (2007).","journal-title":"Int. Anesthesiol. Clin."},{"key":"2000_CR11","doi-asserted-by":"crossref","unstructured":"Surbatovic, M. et al. Cytokine profile in severe gram-positive and gram-negative abdominal sepsis. Sci Rep. 5, 11355 (2015).","DOI":"10.1038\/srep11355"},{"key":"2000_CR12","doi-asserted-by":"publisher","first-page":"84489","DOI":"10.18632\/oncotarget.21060","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget 8, 84489\u201384496 (2017).","journal-title":"Oncotarget"},{"key":"2000_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccc.2018.11.015","volume":"35","author":"C French","year":"2019","unstructured":"French, C. Erythropoietin in critical illness and trauma. Crit. Care Clin. 35, 277\u2013287 (2019).","journal-title":"Crit. Care Clin."},{"key":"2000_CR14","doi-asserted-by":"publisher","first-page":"e0189762","DOI":"10.1371\/journal.pone.0189762","volume":"12","author":"M Zbucka-Kretowska","year":"2017","unstructured":"Zbucka-Kretowska, M., Charkiewicz, K., Goscik, J., Wolczynski, S. & Laudanski, P. Maternal plasma angiogenic and inflammatory factor profiling in foetal Down syndrome. PLoS ONE 12, e0189762 (2017).","journal-title":"PLoS ONE"},{"key":"2000_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1440-1754.1999.00386.x","volume":"35","author":"JM Hilton","year":"1999","unstructured":"Hilton, J. M., Fitzgerald, D. A. & Cooper, D. M. Respiratory morbidity of hospitalized children with Trisomy 21. J. Paediatr. Child Health 35, 383\u2013386 (1999).","journal-title":"J. Paediatr. Child Health"},{"key":"2000_CR16","doi-asserted-by":"publisher","first-page":"e70401","DOI":"10.1371\/journal.pone.0070401","volume":"8","author":"P Fitzgerald","year":"2013","unstructured":"Fitzgerald, P., Leonard, H., Pikora, T. J., Bourke, J. & Hammond, G. Hospital admissions in children with down syndrome: experience of a population based cohort followed from birth. PLoS ONE 8, e70401 (2013).","journal-title":"PLoS ONE"},{"key":"2000_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1542\/peds.107.3.549","volume":"107","author":"WM Southgate","year":"2001","unstructured":"Southgate, W. M., Annibale, D. J., Hulsey, T. C. & Purohit, D. M. International experience with trisomy 21 infants placed on extracorporeal membrane oxygenation. Pediatrics 107, 549\u2013552 (2001).","journal-title":"Pediatrics"},{"key":"2000_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jpc.13214","volume":"52","author":"C Joffre","year":"2016","unstructured":"Joffre, C., Lesage, F., Bustarret, O., Hubert, P. & Oualha, M. Children with Down syndrome: Clinical course and mortality-associated factors in a French medical paediatric intensive care unit. J. Paediatr. Child Health 52, 595\u2013599 (2016).","journal-title":"J. Paediatr. Child Health"},{"key":"2000_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.12669\/pjms.36.5.1743","volume":"36","author":"S Aziz","year":"2020","unstructured":"Aziz, S. et al. Major septal defects: comparative study of Down syndrome and non-Down syndrome infants, before and after surgery. Pak. J. Med. Sci. 36, 925\u2013929 (2020).","journal-title":"Pak. J. Med. Sci."},{"key":"2000_CR20","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ajmg.a.61586","volume":"182","author":"A Baban","year":"2020","unstructured":"Baban, A. et al. Differences in morbidity and mortality in Down syndrome are related to the type of congenital heart defect. Am. J. Med. Genet. A. 182, 1342\u20131350 (2020).","journal-title":"Am. J. Med. Genet. A."},{"key":"2000_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1747-0803.2009.00297.x","volume":"4","author":"H Brun","year":"2009","unstructured":"Brun, H. et al. Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation. Congenit. Heart Dis. 4, 153\u2013159 (2009).","journal-title":"Congenit. Heart Dis."},{"key":"2000_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PCC.0b013e3181b806fc","volume":"11","author":"MG Gaies","year":"2010","unstructured":"Gaies, M. G. et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr. Crit. Care Med. 11, 234\u2013238 (2010).","journal-title":"Pediatr. Crit. Care Med."},{"key":"2000_CR23","doi-asserted-by":"publisher","first-page":"154938","DOI":"10.1016\/j.cyto.2019.154938","volume":"127","author":"D Huggard","year":"2020","unstructured":"Huggard, D. et al. Increased systemic inflammation in children with Down syndrome. Cytokine 127, 154938 (2020).","journal-title":"Cytokine"},{"key":"2000_CR24","unstructured":"Health (Regulation of Termination of Pregnancy) Act 2018. Irish Statute Book: Restricted access to termination of pregnancy (Health Act 2018). Number 31 (2018)."},{"key":"2000_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1542\/peds.2009-3245","volume":"126","author":"JC Fudge Jr.","year":"2010","unstructured":"Fudge, J. C. Jr. et al. Congenital heart surgery outcomes in Down syndrome: analysis of a national clinical database. Pediatrics 126, 315\u2013322 (2010).","journal-title":"Pediatrics"},{"key":"2000_CR26","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jacc.2007.06.014","volume":"50","author":"EM Tucker","year":"2007","unstructured":"Tucker, E. M., Pyles, L. A., Bass, J. L. & Moller, J. H. Permanent pacemaker for atrioventricular conduction block after operative repair of perimembranous ventricular septal defect. J. Am. Coll. Cardiol. 50, 1196\u20131200 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2000_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ppul.20100","volume":"38","author":"CR Esther Jr.","year":"2004","unstructured":"Esther, C. R. Jr. & Barker, P. M. Pulmonary lymphangiectasia: diagnosis and clinical course. Pediatr. Pulmonol. 38, 308\u2013313 (2004).","journal-title":"Pediatr. Pulmonol."},{"key":"2000_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/353858a0","volume":"353","author":"MJ Lenardo","year":"1991","unstructured":"Lenardo, M. J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353, 858\u2013861 (1991).","journal-title":"Nature"},{"key":"2000_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"2000_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon, E. et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122, 920\u2013927 (2010).","journal-title":"Circulation"},{"key":"2000_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1744-313X.2010.00914.x","volume":"37","author":"S Cetiner","year":"2010","unstructured":"Cetiner, S., Demirhan, O., Inal, T. C., Tastemir, D. & Sertdemir, Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int. J. Immunogenet. 37, 233\u2013237 (2010).","journal-title":"Int. J. Immunogenet."},{"key":"2000_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1015-9584(09)60176-7","volume":"25","author":"Y Lei","year":"2002","unstructured":"Lei, Y., Zhen, J., Ming, X. L. & Jian, H. K. Induction of higher expression of IL-beta and TNF-alpha, lower expression of IL-10 and cyclic guanosine monophosphate by pulmonary arterial hypertension following cardiopulmonary bypass. Asian J. Surg. 25, 203\u2013208 (2002).","journal-title":"Asian J. Surg."},{"key":"2000_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCRESAHA.107.153023","volume":"101","author":"T Ito","year":"2007","unstructured":"Ito, T. et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ. Res. 101, 734\u2013741 (2007).","journal-title":"Circ. Res."},{"key":"2000_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1684\/ecn.2012.0307","volume":"23","author":"RM Nateghi","year":"2012","unstructured":"Nateghi, R. M., Douraghi, M., Mohammadi, A. M. & Nikmanesh, B. Altered serum pro-inflammatory cytokines in children with Down\u2019s syndrome. Eur. Cytokine Netw. 23, 64\u201367 (2012).","journal-title":"Eur. Cytokine Netw."},{"key":"2000_CR35","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1016\/j.febslet.2006.10.061","volume":"580","author":"S Perrier","year":"2006","unstructured":"Perrier, S., Darakhshan, F. & Hajduch, E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett. 580, 6289\u20136294 (2006).","journal-title":"FEBS Lett."},{"key":"2000_CR36","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI119488","volume":"99","author":"C Gabay","year":"1997","unstructured":"Gabay, C., Smith, M. F., Eidlen, D. & Arend, W. P. Interleukin 1 receptor antagonist (IL-1Ra) is an acute phase protein. J. Clin. Investig. 99, 2930\u20132940 (1997).","journal-title":"J. Clin. Investig."},{"key":"2000_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","volume":"45","author":"B Becher","year":"2016","unstructured":"Becher, B., Tugues, S. & Greter, M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45, 963\u2013973 (2016).","journal-title":"Immunity"},{"key":"2000_CR38","doi-asserted-by":"publisher","first-page":"556216","DOI":"10.3389\/fped.2020.556216","volume":"8","author":"DU Sweetman","year":"2021","unstructured":"Sweetman, D. U. et al. Neonatal encephalopathy is associated with altered IL-8 and GM-CSF which correlates with outcomes. Front. Pediatr. 8, 556216 (2021).","journal-title":"Front. Pediatr."},{"key":"2000_CR39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ana.410440413","volume":"44","author":"KB Nelson","year":"1998","unstructured":"Nelson, K. B., Dambrosia, J. M., Grether, J. K. & Phillips, T. M. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann. Neurol. 44, 665\u2013675 (1998).","journal-title":"Ann. Neurol."},{"key":"2000_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/9467","volume":"5","author":"HP Gerber","year":"1999","unstructured":"Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623\u2013628 (1999).","journal-title":"Nat. Med."},{"key":"2000_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439\u2013442 (1996).","journal-title":"Nature"},{"key":"2000_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0022-2828(03)00006-3","volume":"35","author":"V Chintalgattu","year":"2003","unstructured":"Chintalgattu, V., Nair, D. M. & Katwa, L. C. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J. Mol. Cell Cardiol. 35, 277\u2013286 (2003).","journal-title":"J. Mol. Cell Cardiol."},{"key":"2000_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.ne.14.030191.002531","volume":"14","author":"LF Reichardt","year":"1991","unstructured":"Reichardt, L. F. & Tomaselli, K. J. Extracellular matrix molecules and their receptors: functions in neural development. Annu. Rev. Neurosci. 14, 531\u2013570 (1991).","journal-title":"Annu. Rev. Neurosci."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02000-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T17:12:47Z","timestamp":1671642767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02000-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1038\/s41390-022-02000-3","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient consent was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}